ScoreWhy is Novelix Pharmaceuticals Ltd ?
1
Weak Long Term Fundamental Strength with an average Return on Equity (ROE) of 0.74%
- Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of -1.17
2
With ROE of 3.7, it has a Very Expensive valuation with a 3.8 Price to Book Value
- The stock is trading at a premium compared to its peers' average historical valuations
- Over the past year, while the stock has generated a return of 146.83%, its profits have risen by 157% ; the PEG ratio of the company is 0.6
Real-Time Research ReportHow much should you sell?
- All quantity irrespective of whether you are making profits or losses
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Retailing)
When to re-enter? - We will constantly monitor the company and review our call based on new data
Is Novelix Pharma. for you?
High Risk, High Return
Absolute
Risk Adjusted
Volatility
Novelix Pharma.
146.83%
2.54
57.82%
Sensex
4.83%
0.41
11.83%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
135.22%
EBIT Growth (5y)
20.40%
EBIT to Interest (avg)
-1.17
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.06
Sales to Capital Employed (avg)
1.13
Tax Ratio
22.76%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
-5.98%
ROE (avg)
0.74%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
102
Industry P/E
0
Price to Book Value
3.77
EV to EBIT
73.64
EV to EBITDA
71.42
EV to Capital Employed
3.93
EV to Sales
1.14
PEG Ratio
0.57
Dividend Yield
NA
ROCE (Latest)
5.34%
ROE (Latest)
3.71%
Loading Valuation Snapshot...
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
No Signal
Bearish
Bollinger Bands
Mildly Bullish
Mildly Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Bullish
Dow Theory
Mildly Bearish
No Trend
OBV
Mildly Bearish
No Trend
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend18What is working for the Company
NET SALES(Latest six months)
Higher at Rs 58.71 cr
PBDIT(Q)
Highest at Rs 0.70 cr.
PBT LESS OI(Q)
Highest at Rs 0.69 cr.
PAT(Q)
Highest at Rs 0.53 cr.
EPS(Q)
Highest at Rs 0.37
0What is not working for the Company
NO KEY NEGATIVE TRIGGERS
Loading Valuation Snapshot...
Here's what is working for Novelix Pharma.
Net Sales - Latest six months
At Rs 58.71 cr has Grown at 1,187.50%
Year on Year (YoY)MOJO Watch
Sales trend is very positive
Net Sales (Rs Cr)
Net Sales - Latest six months
Higher at Rs 58.71 cr
than preceding 12 month period ended Sep 2025 of Rs 30.72 crMOJO Watch
In the half year the company has already crossed sales of the previous twelve months
Net Sales (Rs Cr)
Operating Profit (PBDIT) - Quarterly
Highest at Rs 0.70 cr.
in the last five quartersMOJO Watch
Near term Operating Profit trend is positive
Operating Profit (Rs Cr)
Profit Before Tax less Other Income (PBT) - Quarterly
Highest at Rs 0.69 cr.
in the last five quartersMOJO Watch
Near term PBT trend is positive
PBT less Other Income (Rs Cr)
Profit After Tax (PAT) - Quarterly
Highest at Rs 0.53 cr.
in the last five quartersMOJO Watch
Near term PAT trend is positive
PAT (Rs Cr)
Earnings per Share (EPS) - Quarterly
Highest at Rs 0.37
in the last five quartersMOJO Watch
Increasing profitability; company has created higher earnings for shareholders
EPS (Rs)
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
